Standard BioTools

About:

Standard BioTools is a biotech tools company that creates microfluidic-based chips and instrumentation for biological research.

Website: https://www.standradbiotools.com

Twitter/X: fluidigm

Top Investors: Invus, EDBI, Versant Ventures, Viking Global Investors, Cross Creek

Description:

Standard BioTools, previously known as Fluidigm, is driven by a bold vision – unleashing tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the Company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies that help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy.

Total Funding Amount:

$375M

Estimated Revenue Range:

$100M to $500M

Headquarters Location:

South San Francisco, California, United States

Founded Date:

1999-01-01

Contact Email:

socialmedia(AT)fluidigm.com

Founders:

Gajus Worthington

Number of Employees:

251-500

Last Funding Date:

2022-01-24

IPO Status:

Public

© 2025 bioDAO.ai